An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows.

What Happened: A post from Musk on Christmas shared his latest take on weight-loss drugs and could provide a suggestion to anyone trying to decide between Eli Lilly's (NYSE:LLY) Mounjaro and Novo Nordisk's (NYSE:NVO) Ozempic for weight-loss treatment.

The post from Musk called himself "Ozempic Santa." Despite the post labeled with Ozempic, Musk admitted in the comments that it is actually Mounjaro that he has taken for weight-loss support.

"Technically, Mounjaro, but that doesn't have the same ring to it," Musk tweeted.

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also increasing in popularity as weight-loss options for people around the world.

When it comes to the two weight-loss drug options, Musk shared his personal takes on both.

"High doses of Ozempic made me fart & burp like Barney from The Simpson's. Mounjaro seems to have fewer side effects and be more effective," Musk said.

With the Christmas posts, Musk has now shared publicly that he has tried Mounjaro, Ozempic and Wegovy, another treatment from Novo Nordisk.

You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — check out five stocks flying under the radar that deserve your attention.

Why It's Important: Musk's Christmas post, continues his public support for weight-loss drugs.

After "South Park" aired a special mocking weight-loss drugs as a luxury for the wealthy, the billionaire predicted these medications would become more affordable over time.

In May, responding to a post about childhood obesity, Musk signaled support for weight-loss medications by posting "Ozempic ftw" (for the win), suggesting these drugs could be a future tool against the epidemic.

The billionaire's future battle could be convincing Robert F. Kennedy Jr. and Donald Trump that Americans need more access to affordable weight-loss drugs like Mounjaro. Musk is arguing for more access while Kennedy, who Trump said will be nominated to lead the Health and Human Services, supports healthier eating to fight obesity.

NVO, LLY Price Action: Novo Nordisk stock trades at $87.56 at the time of writing. The stock is down 14% year-to-date in 2024 and up 200.6% over the last five years.

Eli Lilly stock trades at $795.87 at the time of writing. The stock is up 34% year-to-date in 2024 and up 504.7% over the last five years.

• Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments

Photo: Shutterstock